Alembic's revenues down 3% as API exports slide
This article was originally published in Scrip
Alembic of India has reported a 3% decline in sales to Rs2.83 billion ($60.9 million) for the quarter ended 30 June, hit by a slide in exports of active pharmaceutical ingredients (APIs). Net profits for the quarter declined to Rs114.8 million compared with Rs122.5 million in the corresponding quarter of the previous fiscal year.
You may also be interested in...
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."